Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Launched by NATIONAL HEART CENTRE SINGAPORE · Jan 27, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the heart responds to conditions that cause thickening of the heart muscle, particularly in people with high blood pressure. The focus is on understanding a specific type of heart muscle damage called myocardial fibrosis, which can happen over time due to untreated high blood pressure. The researchers will use advanced MRI scans and blood tests to examine this condition in 2000 patients who have hypertension, making it one of the largest studies of its kind. About half of the participants will be asked to return for follow-up assessments after a year to see any changes.
To participate in this study, you need to be at least 21 years old and have been diagnosed with high blood pressure, either recently or persistently, despite taking medication. However, certain medical conditions, such as severe kidney problems or specific heart diseases, may exclude you from joining. If you're eligible, you'll undergo some tests, including MRI scans, to help researchers learn more about how high blood pressure affects the heart over time. This study aims to provide valuable insights that could lead to better treatments and understanding of heart health for those with hypertension.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 21 years and over
- • 2. Physician diagnosed essential hypertension, on at least 1 medication for blood pressure control
- • 3. Newly diagnosed hypertension: systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) on at least 2 office visits (Weber 2013) and not started on any anti hypertensive medications at time of ambulatory blood pressure monitoring
- • 4. Resistant hypertension: persistent systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) despite on at least 3 anti-hypertensive medications (Jennings 2013; Weber 2013)
- Exclusion Criteria:
- • 1. Known secondary hypertension: renal causes (renal artery stenosis, chronic renal failure); endocrine causes (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism); cardiac causes (coarctation of the aorta)
- • 2. Contraindications to cardiovascular magnetic resonance: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF \<30ml/min/1.73m2), claustrophobia and women who are pregnant or breast-feeding
- • 3. Limited life expectancy
- • 4. On-going unstable medical conditions: hypertensive crisis, acute coronary syndromes or acute heart failure
- • 5. History of coronary artery disease, ischemic heart disease
- • 6. History of transient ischemic attacks or cerebrovascular events
- • 7. History of atrial fibrillation
- • 8. History of heart failure
About National Heart Centre Singapore
The National Heart Centre Singapore (NHCS) is a leading institution dedicated to advancing cardiovascular care and research in Singapore and the Asia-Pacific region. As a premier clinical trial sponsor, NHCS is committed to improving heart health through innovative research and clinical excellence. The center specializes in a wide range of cardiovascular conditions, leveraging cutting-edge technology and a multidisciplinary approach to develop and evaluate new therapies. With a strong emphasis on patient-centered care, NHCS collaborates with various stakeholders to enhance clinical outcomes and contribute to the global body of cardiovascular knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Calvin WL Chin, MBBS, PhD
Principal Investigator
National Heart Centre Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials